SG has demonstrated significant clinical efficacy in heavily pretreated metastatic triple-negative breast cancer (Bardia et al. 2021a), and its mechanism—targeting TROP2 with a topoisomerase I inhibitor payload (SN-38)—is relevant for tumors that express TROP2. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.